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Abstract
Background: A large measles outbreak occurred in Italy in 2002–2003. This study evaluates the
health burden and economic impact of measles-related hospitalizations in Italy during the specified
period.
Methods: Hospital discharge abstract data for measles hospitalizations in Italy during 2002–2003
were analysed to obtain information regarding number and rates of measles hospitalizations by
geographical area and age group, length of hospital stay, and complications. Hospitalization costs
were estimated on the basis of Diagnosis-Related Groups.
Results: A total of 5,154 hospitalizations were identified, 3,478 (67%) of which occurred in
children <15 years of age. Most hospitalizations occurred in southern Italy (71 %) and children
below 1 year of age presented the greatest hospitalization rates (46.2/100,000 and 19.0/100,000,
respectively in 2002 and 2003). Pneumonia was diagnosed in 594 cases (11.5%) and encephalitis in
138 cases (2.7%). Total hospital charges were approximately € 8.8 million.
Conclusion: The nationwide health burden associated with measles during the 2002–2003
outbreak was substantial and a high cost was incurred by the Italian National Health Service for the
thousands of measles-related hospitalizations which occurred. By assuming that hospital costs
represent 40–50% of the direct costs of measles cases, direct costs of measles for the two years
combined were estimated to be between €17.6 – 22.0 million, which equates to the vaccination of
1.5–1.9 million children (3–4 birth cohorts) with one dose of MMR. The high cost of measles and
the severity of its complications fully justify the commitment required to reach measles elimination.
Background
In Italy, measles vaccine was first introduced in 1979 and
combined measles-mumps-rubella (MMR) vaccines
became available in the early 1990s. Initially, routine
administration of one dose of measles vaccine to all chil-
dren aged ≥ 15 months was recommended, while the cur-
rent two dose schedule (one dose at age 12–15 months
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in 1999 [1].
Despite the existence of national recommendations, how-
ever, each of the country's 21 regions was responsible for
implementation of strategies regarding non-compulsory
vaccinations, including measles. This contributed to non
uniform vaccine coverage rates observed across Italy, with
lower rates observed mainly in southern regions [2].
National coverage for one dose of MMR vaccine in chil-
dren aged 12–24 months also remained inadequate and
was estimated to be 56% in 1998 [3] and 74% in 2001 [4].
Due to suboptimal coverage rates, a large proportion of
individuals remained susceptible to measles and in 2002,
a large outbreak occurred in Campania, a region of south-
ern Italy [5]. The outbreak then spread to other regions,
prevalently in southern Italy, with an estimated national
incidence, in children below 15 years of age, of 738/
100,000 in 2002 and 544/100,000 in 2003, correspond-
ing to over 100,000 estimated cases in this age group [6].
It is well known that measles infection can cause serious
complications and between 1.4% and 19.0% of measles
cases that occur in industrialized countries require hospi-
talization [7-11]. Many measles-related hospitalizations
were therefore expected to have occurred across Italy in
2002 and 2003.
In addition to their disease burden, hospitalized measles
cases impose an economical burden to the healthcare sys-
tem and to society as a whole. The majority of economic
costs associated with measles have, in fact, been attributed
to the cost of hospitalizing patients [10]. In order to
obtain information on the health burden and economic
impact of a measles outbreak in Italy, therefore, we evalu-
ated national discharge data regarding measles-related
hospitalizations that occurred in the years 2002–2003.
Methods
Sources of data
Hospital discharge abstract data for measles-related hospi-
talizations that occurred in Italy between January 1st 2002
and December 31st 2003, was obtained from the national
discharge abstract data bank, held by the Ministry of
Health. This database contains administrative and health
data regarding hospital admissions, that all public and
privately-owned hospitals in Italy are legally required to
report [12].
For each admission, a main discharge diagnosis is
reported; this represents the clinical condition which took
up the greatest amount of resources and therefore
involved the greatest cost for the hospital. Up to five addi-
tional secondary diagnoses may be listed.
Diagnoses are coded by using International Classification
of Diseases-Clinical Modification, 9th edition (ICD9-CM)
nomenclature. Measles-related codes include the follow-
ing: postmeasles encephalitis (055.0), postmeasles pneu-
monia (055.1), postmeasles otitis media (055.2), measles
keratoconjunctivitis (055.71), measles with other speci-
fied complication (055.79), measles with unspecified
complication (055.8) and measles without mention of
complication (code 055.9).
In this study, we included all admissions with at least one
measles-related main or secondary discharge diagnosis.
For each of these hospitalizations, we obtained the fol-
lowing data: hospital code, age, gender, municipality,
province and region codes, citizenship, admission and
discharge dates, type of admission (i.e. emergency or ordi-
nary), payer of hospital expenses (i.e. National Health
Service or other), discharge status (i.e. death, ordinary or
voluntary discharge, transferred to other acute care hospi-
tal), main discharge diagnosis, secondary diagnoses (if
present), Diagnosis Related Group (DRG).
Data provided by the Ministry of Health did not contain
any patient identifiers and was therefore completely
anonymous. Ethical approval was therefore not required
for this study [13].
Population data for 2002 and 2003 was obtained from
the Italian Institute of Statistics (ISTAT), which registers
the national and regional population, by age group, as of
the 1st of January for each year [14].
Diagnoses/Complications
A listing was made of all main and secondary discharge
diagnoses recorded in measles hospitalizations.
For the purposes of this study, non complicated measles
cases were defined as cases with a main discharge diagno-
sis of "measles without mention of complication" (code
055.9) and without any secondary diagnoses. In the
remaining cases, the type and frequency of complications
were assessed by taking into account both main and sec-
ondary diagnoses. In addition to measles-specific codes,
we included in the complications analysis other recorded
ICD9-CM codes that represented possible complications
of measles (see Additional File 1: ICD9-CM codes
recorded as main and secondary discharge diagnoses in
measles hospitalizations, Italy 2002–2003). In fact, ICD9-
CM codes for complicated measles (055.0–055.8) do not
include all possible complications of the disease; for
example, thrombocytopenia is a possible complication of
measles but there is no specific ICD9-CM code for this
clinical condition when it occurs in a patient with mea-
sles.Page 2 of 9
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The costs of measles hospitalizations, at the national level
and for each region, were estimated by use of DRG-based
cost per case. The DRG system is a classification system
designed to group hospital patients into categories which
are clinically homogeneous with regard to the consump-
tion of hospital resources. It is used, among other things,
as a system of payment for the operating costs of hospital
inpatient stays, based on predetermined rates [15]. Upon
discharge from hospital, each patient is classified into a
DRG on the basis of clinical information provided on the
discharge abstract form. Each DRG has a payment weight
assigned to it, based on the average resources used to treat
patients in that DRG. Except for certain patients with
exceptionally high costs (called outliers), the hospital is
then paid a flat rate for the DRG. Separate rates exist for 1-
day, ordinary (that is, with a length of stay > 1 day but <
threshold value which defines outlier admissions) and
outlier admissions. Because each of the 21 Italian regions
establishes its own DRG rates, these of course vary
between regions. For this reason, we used the rates agreed
upon by all regions for the inter-regional reimbursement
scheme regarding patients hospitalized out of their own
region [16].
For the present study, we listed all DRGs attributed to
measles-related admissions in 2002–2003, in each region,
and calculated the number of 1-day, ordinary, and outlier
admissions within each specific DRG. By using the above-
mentioned DRG rates, we then calculated the costs of
measles-related admissions.
Data Analysis
Discharge abstract data were analyzed to obtain the fol-
lowing information:
- number and rates of measles hospitalizations per
100,000 population, by age group, for 2002 and 2003.
Direct age-standardized hospitalization rates were calcu-
lated, by region and geographical area (North, Centre,
South), using the Italian mean population of the two
years combined as the standard population
- median age of cases
- distribution of diagnoses by age group
- length of hospital stay
- costs of measles hospitalizations, mean cost per admis-
sion day and mean cost per hospitalized case.
Categorical variables were compared using the χ2 test. The
Kruskal Wallis test was used to compare continuous vari-
ables. Chi square for trend test was performed to evaluate
the linear association between diagnoses and age groups.
Results
A total of 5,154 measles-related hospitalizations were
identified, 3,072 of which occurred in 2002 and 2,082 in
2003. The median age of cases was 9 years (range 0–92
years).
Main discharge diagnosis
Measles was registered as the main discharge diagnosis in
most hospitalizations (Table 1). This proportion was sim-
ilar in the three geographical areas (North 87.2%, Centre
89.6%, South 86.6%, p = 0.05).
In approximately 70% of cases where measles was regis-
tered as a secondary diagnosis, the main diagnosis was
respiratory infections/insufficiency or other symptoms/
conditions compatible with measles complications (Table
1).
No statistically significant differences were observed in
the median age of cases with and without a main dis-
charge diagnosis of measles (respectively 9 and 7 yrs, p =
0.12). In both groups, approximately 52% of patients
were male.
Age-specific rates of hospitalizations
The hospitalization rate was 1.5 times higher in 2002 than
in 2003 (Table 2). Most hospitalizations occurred in chil-
dren <15 years of age (67.5%). In both years, children < 1
year of age had the highest hospitalization rates and rates
decreased with increasing age.
Table 1: Main discharge diagnoses in measles hospitalizations. Italy, 2002–2003
Main Diagnosis N. hospitalizations (%)
Measles (ICD9-CM codes 055.0–055.9) 4496 (87.2)
Respiratory infections or insufficiency 211 (4.1)
Other symptoms/conditions compatible with measles complications 246 (4.8)
Other medical conditions* 201 (3.9)
Total 5154 (100.0)
* including tumours, immune deficiency disorders, diabetes, other acute/chronic disordersPage 3 of 9
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Figure 1 shows the regional standardized hospitalization
rates/100,000 population, for 2002 and 2003. In both
years, over 71% of hospitalizations occurred in southern
Italy, where hospitalization rates were found to be 5–9
times greater than in northern Italy (Table 3). Differences
were especially marked in children below 10 years of age,
with 5–21-fold higher incidence rates in southern with
respect to northern regions. By contrast, the observed gap
between northern and southern rates was smallest (3–4-
fold) in the over-19 years age group.
Diagnoses/Complications
Of 5,154 hospitalizations, 2,390 (46.4%) had a single dis-
charge diagnosis of "measles without mention of compli-
cation" (ICD9-CM code 055.9). The remaining 2,764
hospitalizations included admissions with either a single
discharge diagnosis of complicated measles (ICD9-CM
codes 055.0–055.8: 471 admissions) or with two or more
discharge diagnoses (2,293 admissions).
Table 4 shows the age distribution of clinical discharge
diagnoses (N. = 6,496) reported for all hospitalizations.
Over 50% of admissions involving individuals > 15 years
of age were for non-complicated measles. Pneumonia was
the most common complication and, together with otitis
media and other respiratory tract conditions, was found to
be more frequent in children < 10 years of age. On the
other hand, encephalitis was more frequent in adolescents
and adults.
Of note are the 20 listed diagnoses of spontaneous or
threatened abortion or other antepartum or fetal compli-
cations. The category "other measles complications"
includes conditions (e.g. myocarditis, pericarditis) listed
with a frequency of less than 20 diagnoses each.
Two deaths were registered in the Campania region,
involving two female children aged respectively < 1 year
and 11 years. Both deaths occurred as a result of respira-
tory insufficiency.
Length of stay
Total admission time for the 5,154 measles hospitaliza-
tions was 27,017 days. The median length of stay was 4
days (range 1 – 303 days) and approximately 95% of
admissions lasted ≤ 10 days. Median length of stay was 4
days in all age groups ≤ 19 years, and 5 days in cases aged
>19 years (p < 0.001).
Costs
Total hospital charges for the 5,154 admissions were
approximately € 8.8 million (Table 5). The payer of hos-
pital expenses was the National Healthcare Service (NHS)
in 98.8% of cases (5,090 admissions).
Each hospitalization cost, on average, an estimated
€1,700. Non complicated measles cases cost on average
€1,429 while the average cost per case of all other hospi-
talizations was €1,960. An even higher mean cost per case
(€2,721) was observed in hospitalizations with a single
discharge diagnosis of complicated measles (ICD9-CM
codes 055.0–055.8).
Each admission day cost an estimated €327. The mean
costs per hospital day and per hospitalized case were
found to be consistent in the three different geographical
areas (North, Centre, South).
Discussion
Measles is now a rare disease in industrialised countries,
and measles elimination targets have been set in the vari-
ous World Health Organization (WHO) regions, such as
Europe and the Americas; nevertheless, measles outbreaks
continue to occur in under-vaccinated populations [17].
This study represents an important source of data regard-
ing the health impact and economic costs of measles hos-
pitalizations during a measles outbreak in Italy. Data was
Table 2: Age distribution of measles hospitalizations. Italy, 2002–2003.
Age group (years) 2002 2003
N. hospitalizations (%) N. hospitalizations/
100,000 population
N. hospitalizations (%) N. hospitalizations/
100,000 population
<1 241 (7.8) 46.2 102 (4.9) 19.0
1 – 4 834 (27.1) 39.8 382 (18.3) 17.9
5 – 9 781 (25.4) 29.2 379 (18.2) 14.3
10 – 14 430 (14.0) 15.3 329 (15.8) 11.6
15 – 19 258 (8.4) 8.8 313 (15.0) 10.8
≥ 20 528 (17.2) 1.1 577 (27.7) 1.2
Total 3072 (100.0) 5.4 2082 (100.0) 3.6
Note: All differences observed among age-groups were statistically significant (p < 0.05), with the exception of: 2003, age groups < 1 vs. 1–4 years 
and age groups 10–14 vs. 15–19 years.Page 4 of 9
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which has been shown to be >85% sensitive in assessing
the frequency of disease conditions requiring hospitaliza-
tion [18]. This type of database is available in a number of
countries and, in countries using DRG costs to finance
hospitals, has also been shown to be a reliable source of
cost information for calculating the total cost of patient
stays [19]. DRGs or similar grouping systems are well
established in the USA and Australia and, over the past
twenty years have been introduced in most European
countries as instruments for reimbursement of hospital
costs [20].
Recent studies have estimated the economic costs of mea-
sles cases and measles control in industrialized countries,
mainly on the basis of various assumptions regarding
measles incidence, vaccination coverage, hospitalization
rates and treatment costs in different countries [11,21-24].
However, to our knowledge no nation- wide studies have
been performed to directly evaluate the costs of measles-
related hospitalizations on the basis of DRG rates.
Over two years, total direct hospitalization costs in Italy
were estimated to be approximately €8.8 million, 98.8%
of which (€8.7 million) were incurred by the NHS. The
average cost of a hospitalized case, from the NHS perspec-
tive, is consistent with that estimated in another national
study [24]. Costs per hospitalized case and per hospitali-
zation day were comparable to those estimated for Can-
ada, but higher than those estimated in two other
European countries (Netherlands and the UK) [22]. This
reflects the variability of hospital costs in different coun-
tries and may indicate the existence of higher hospital
costs in Italy compared to other European countries.
It is well known that, in economic terms, the main advan-
tage of measles vaccination is represented by the savings
that may be achieved by preventing measles cases
[23,25,26]. In Italy, vaccination coverage remains sub-
optimal, and higher per capita measles costs have been
reported, with respect to countries with better measles
control [21]. Hospitalizations have been estimated to
account for 40–50% of direct Italian NHS costs of measles
Standardised rate of measles hospitalizations per 100,000 inhabitants, by regionFigure 1
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tions. In 2002–2003, therefore, total direct measles costs
in Italy may be considered to have been between €17.6 –
22.0 million. Approximately 97% of MMR vaccine is pur-
chased and provided by the NHS [27] and the mean cost
of one dose of vaccine in 2002 was €11.5. With the direct
measles costs incurred by the Italian NHS in 2002–2003,
therefore, approximately 1.5 to 1.9 million children,
equivalent to 95% of 3 to 4 birth cohorts, could have been
vaccinated with one dose of MMR vaccine, and many
measles cases and hospitalizations may have been
avoided. Administration of MMR would additionally
have prevented many mumps and rubella cases and their
related costs.
This outbreak caused more than 5,000 hospital admis-
sions over two years. Close to 90% of these hospitaliza-
tions had measles as a main discharge diagnosis, and no
significant differences in terms of age and geographical
distribution were found between these cases and those
with measles as a secondary diagnosis. Most of the latter
cases had a main diagnosis of respiratory infections or
Table 4: Diagnoses in measles hospitalizations, by age. Italy 2002–2003.
Age group in years
<1 1–4 5–9 10–14 15–19 ≥ 20 Total p-value
N. Hospitalizations 343 1216 1160 759 571 1105 5154



































































































































































































Total N. Diagnoses 418 1475 1392 901 695 1615 6496
Note: For each diagnosis, percentages are calculated over the number of hospitalizations in each age group. Total percentages for each column exceed 100 because more than 
one discharge diagnosis may be listed for each hospitalization.
Table 3: Age-specific measles hospitalization rates by geographical area. Italy 2002 and 2003.
N. hospitalizations/100 000 population
Age group (yrs) 2002 2003
North Centre South North Centre South
<1 4.4 49.2 90.7 6.4 15.3 35.1
1–4 5.2 36.0 78.2 3.6 10.4 37.2
5–9 4.6 28.4 52.5 2.7 8.2 28.4
10–14 3.1 19.5 23.9 2.8 7.5 20.8
15–19 2.0 13.5 12.5 5.0 8.2 16.8
≥ 20 0.4 2.0 1.7 0.6 2.1 2.0
Total 1.0 6.3 9.4 1.2 2.8 6.5
Note: For each age group, differences observed among geographical areas were all statistically significant (p < 0.001).Page 6 of 9
(page number not for citation purposes)
BMC Public Health 2007, 7:169 http://www.biomedcentral.com/1471-2458/7/169other conditions compatible with measles complications,
while only a minority of hospitalizations had a main diag-
nosis that was not related to measles.
Almost 50% of patients were hospitalized for non compli-
cated measles. Although we cannot precisely identify the
reason for admission in these cases, nor can we exclude
that at least part of these admissions may have been inap-
propriate, these findings confirm that measles can be
severe enough to require hospitalization even in industr-
ialised countries and when specific complications are not
present [7].
Over 65% of hospitalizations occurred in children aged
0–14 years and the greatest hospitalization rate occurred
in children below 1 year of age. This was to be expected
since, in the presence of suboptimal vaccine coverage,
most measles cases continue to occur in small children
and the disease is generally more severe in infants [28].
A large number of pneumonia and encephalitis cases were
identified. The latter should be underscored, since long
term sequelae of measles encephalitis are reported to
occur in 20–30% of cases [29,30]; this implies that
between 28 to 41 of the 138 encephalitis cases may have
subsequently developed permanent disabilities. Unfortu-
nately, we do not have data on the outcome of these cases.
Finally, even though the number of deaths was small if
compared to other causes of death, it must be underlined
that these are preventable deaths that occurred in small
children.
This study presents several limitations. The first limitation
is that examined data refers to hospitalized cases with a
discharge diagnosis of measles made on clinical grounds,
without laboratory confirmation of infection. It is possi-
ble that some of these cases may have been misdiagnosed
and that the total number of measles-related hospitaliza-
tions may therefore have been overestimated. Neverthe-
less, the positive predictive value of a clinical diagnosis of
measles is higher in an epidemic period than in periods of
low incidence [31].
A second limitation of the study is due to possible coding
errors present in the discharge abstract forms. The hospital
discharge abstract database relies on translation of physi-
cian discharge diagnoses into ICD9-CM codes, and differ-
ent physicians may code for a specific diagnosis in
different ways. Hospital medical charts were not reviewed
in this study. It is possible, therefore, that at least some
measles-related diagnoses may have been missed because
codified with codes other than those relating to measles.
For example, a total of 4 measles deaths were reported in
2002 in the Campania region [32] while only 2 appeared
in the database. Although it is possible that the two addi-
tional deaths may have occurred outside the hospital set-
ting, they also may have been coded with a discharge
diagnosis other than measles.
A third limitation is represented by the fact that individual
identification data for each admitted patient could not be
sent to us for privacy reasons and so we were not able to
identify patients who had been admitted more than once
for the same condition. This, however, did not in any way
affect our cost calculations nor did it affect calculations
regarding the number of admission days and the median
length of stay.
Conclusion
The findings of this study highlight the substantial nation-
wide health burden associated with measles during the
2002–2003 outbreak, and its related costs. The study also
shows how, in countries using DRG costs to finance hos-
pitals, these may be used to calculate the cost of inpatient
stays for a specific disease.
Measles hospitalizations in Italy in 2002–2003 mainly
occurred in central and southern regions. This reflects the
different regional vaccination strategies adopted in the
past which have led, with a few exceptions, to higher cov-
erage levels in northern regions with respect to the rest of
the country [2]. A seroprevalence survey conducted in the
late 1990s found a significantly higher proportion of chil-
dren susceptible to measles in regions with coverage rates
below 70%, and these regions were prevalently located in
central and southern Italy [3,33].
Table 5: Length of stay and costs of measles hospitalizations, by geographical area. Italy 2002–2003.
Geographical Area N. hospitalizations Median length of 
stay (days)
Total cost (€) Mean cost per 
hospital day (€)
Mean cost per 
hospitalized case (€)
North 541 4 1,066,723 338.97 1971.76
Centre 946 5 1,755,038 304.75 1855.22
South 3667 4 6,011,529 331.93 1639.36
ITALY 5154 4 8,833,302 326.95 1700.14Page 7 of 9
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age rates for measles and reducing regional differences
have been undertaken at the national level. In 2002, MMR
vaccination was included in the list of "essential health
interventions" that all regions must provide free of charge
within the NHS [34] and in 2003, the National Plan for
the Elimination of Measles and Congenital Rubella was
launched. Key strategies of the plan include programmes
to achieve and sustain high coverage with 2 doses of MMR
vaccine administered at 12–15 months and 5–6 years of
age, implement a nationwide 'catch-up' vaccination cam-
paign, and strengthen measles surveillance.
Since implementation of the elimination plan, MMR cov-
erage rates in children by 2 years of age have been improv-
ing across Italy, and in 2005 reached 87%. In the same
year a record low number of 108 measles cases were
reported. Substantial progress has therefore been made
towards the national elimination targets. However, in
2006, various clusters of measles cases occurred in under-
vaccinated Roma/Sinti populations in different Italian
regions [35]. These clusters are reminders that special
attention is warranted for underserved population groups
that have few or no contact with the health care system.
Additional efforts are still needed, therefore, to reach the
WHO measles elimination target set for 2010 in the Euro-
pean region. Evidence based recommendations for
increasing coverage of universal vaccinations, such as
reminder and/or recall systems by healthcare providers
and provider-based interventions for addressing missed
opportunities should be reinforced. The high cost of mea-
sles and the severity of its complications fully justify the
measles elimination effort.
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